A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

NCT03207867 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

315

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

NSCLC, Non Small Cell Lung Cancer
RCC, Renal Cell Cancer
Pancreatic Cancer
Urothelial Cancer
Head and Neck Cancer
DLBCL, Diffused Large B Cell Lymphoma
MSS, Microsatellite Stable Colon Cancer
TNBC, Triple Negative Breast Cancer
Melanoma
mCRPC, Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG: NIR178
DRUG: PDR001

Sponsor

Novartis Pharmaceuticals